IDenta Corp. (IDTA)
USD 0.36
(-40.0%)
USD 0.36
(-40.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 662.97 Thousand USD | -16.53% |
| 2022 | 858.07 Thousand USD | 6.18% |
| 2021 | 808.1 Thousand USD | 54.45% |
| 2020 | 523.23 Thousand USD | -4.06% |
| 2019 | 545.36 Thousand USD | 22.72% |
| 2018 | 444.39 Thousand USD | 0.81% |
| 2017 | 440.8 Thousand USD | -12.75% |
| 2016 | 505.23 Thousand USD | -4.34% |
| 2015 | 528.17 Thousand USD | -23.63% |
| 2014 | 691.63 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 185.76 Thousand USD | 4.33% |
| 2024 Q1 | 178.05 Thousand USD | 36.4% |
| 2023 FY | 716.21 Thousand USD | -16.53% |
| 2023 Q4 | 130.53 Thousand USD | -18.96% |
| 2023 Q3 | 161.06 Thousand USD | -16.51% |
| 2023 Q1 | 212.9 Thousand USD | -7.53% |
| 2023 Q2 | 192.91 Thousand USD | -9.39% |
| 2022 Q2 | 226.28 Thousand USD | 14.45% |
| 2022 FY | 858.07 Thousand USD | 6.18% |
| 2022 Q4 | 230.24 Thousand USD | 11.69% |
| 2022 Q3 | 206.14 Thousand USD | -8.9% |
| 2022 Q1 | 197.7 Thousand USD | -15.17% |
| 2021 Q3 | 198.15 Thousand USD | 25.89% |
| 2021 Q2 | 157.4 Thousand USD | -14.12% |
| 2021 FY | 808.1 Thousand USD | 54.45% |
| 2021 Q4 | 233.07 Thousand USD | 17.62% |
| 2021 Q1 | 183.27 Thousand USD | -6.7% |
| 2020 Q4 | 196.44 Thousand USD | 74.59% |
| 2020 FY | 523.23 Thousand USD | -4.06% |
| 2020 Q1 | 107.82 Thousand USD | -28.68% |
| 2020 Q2 | 99.91 Thousand USD | -7.33% |
| 2020 Q3 | 112.51 Thousand USD | 12.61% |
| 2019 Q3 | 140.32 Thousand USD | 5.63% |
| 2019 Q1 | 125.36 Thousand USD | -4.35% |
| 2019 FY | 545.36 Thousand USD | 22.72% |
| 2019 Q4 | 151.18 Thousand USD | 7.74% |
| 2019 Q2 | 132.83 Thousand USD | 5.97% |
| 2018 Q3 | 96.84 Thousand USD | -5.26% |
| 2018 FY | 444.39 Thousand USD | 0.81% |
| 2018 Q4 | 131.06 Thousand USD | 35.34% |
| 2018 Q2 | 102.21 Thousand USD | -6.71% |
| 2018 Q1 | 109.57 Thousand USD | 5.15% |
| 2017 FY | 440.8 Thousand USD | -12.75% |
| 2017 Q1 | 114 Thousand USD | 0.0% |
| 2017 Q2 | 110.83 Thousand USD | -2.78% |
| 2017 Q3 | 104.43 Thousand USD | -5.78% |
| 2017 Q4 | 104.2 Thousand USD | -0.22% |
| 2016 FY | 505.23 Thousand USD | -4.34% |
| 2015 FY | 528.17 Thousand USD | -23.63% |
| 2014 FY | 691.63 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | 36.799% |
| Arrayit Corporation | 6.19 Million USD | 89.303% |
| Atlantic International Corp. | 5.57 Million USD | 88.115% |
| Biocept, Inc. | 29.4 Million USD | 97.745% |
| Bioqual, Inc. | 7.44 Million USD | 91.1% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | 14.138% |
| DermTech, Inc. | 104.01 Million USD | 99.363% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 99.602% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 97.07% |
| iMD Companies, Inc. | 151.8 Thousand USD | -336.717% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 96.723% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -1605.139% |
| InVitro International | 661.32 Thousand USD | -0.25% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 90.66% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -1040.857% |
| Medical Imaging Corp. | 1.91 Million USD | 65.329% |
| NovelStem International Corp. | 3.53 Million USD | 81.26% |
| Optigenex Inc. | 1.28 Million USD | 48.522% |
| PharmChem, Inc. | 2.93 Million USD | 77.382% |
| Proteome Sciences plc | 3.26 Million USD | 79.713% |
| Response Genetics, Inc | 25.31 Million USD | 97.382% |
| Rennova Health, Inc. | 7.67 Million USD | 91.365% |
| RushNet, Inc. | 1.78 Million USD | 62.948% |
| ScreenPro Security Inc. | 3.23 Million USD | 79.531% |
| Stella Diagnostics Inc. | 11.42 Million USD | 94.198% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 90.971% |
| Todos Medical Ltd. | 14.05 Million USD | 95.284% |